VIDEO: RBX2660 restores microbiome, bile acid composition in C. difficile infection

SAN DIEGO — RBX2660, an investigational live biotherapeutic, restored microbiome and bile acid composition concurrent with clinical response in patients with Clostridioides difficile, according to research at Digestive Disease Week 2022.“This poster is three different takes on how RBX2660 is aimed at restoring the microbiome and the data that we saw in three clinical trials,” Ken Blount, PhD, chief scientific officer at Rebiotix, a Ferring company, and vice president of microbiome research at Ferring Pharmaceuticals, said in a Healio video exclusive. “This is theRead More